AYVAKIT (avapritinib)
Indolent Systemic Mastocytosis
Key Facts
About Blueprint Medicines
Blueprint Medicines is a precision therapy company acquired by Sanofi in 2025, operating as a focused subsidiary with enhanced global resources. The company has successfully commercialized AYVAKIT® (avapritinib) for systemic mastocytosis and GIST, validating its kinase-focused discovery platform. Its strategy centers on scaling this platform to expand into larger allergic/inflammatory disease populations and solid tumors, while incorporating new modalities like targeted protein degradation and AI/ML tools to drive future pipeline growth.
View full company profileAbout Blueprint Medicines
Blueprint Medicines is a precision therapy company acquired by Sanofi in 2025, operating as a focused subsidiary with enhanced global resources. The company has successfully commercialized AYVAKIT® (avapritinib) for systemic mastocytosis and GIST, validating its kinase-focused discovery platform. Its strategy centers on scaling this platform to expand into larger allergic/inflammatory disease populations and solid tumors, while incorporating new modalities like targeted protein degradation and AI/ML tools to drive future pipeline growth.
View full company profileAbout Blueprint Medicines
Blueprint Medicines is a precision therapy company acquired by Sanofi in 2025, operating as a focused subsidiary with enhanced global resources. The company has successfully commercialized AYVAKIT® (avapritinib) for systemic mastocytosis and GIST, validating its kinase-focused discovery platform. Its strategy centers on scaling this platform to expand into larger allergic/inflammatory disease populations and solid tumors, while incorporating new modalities like targeted protein degradation and AI/ML tools to drive future pipeline growth.
View full company profileTherapeutic Areas
Other Indolent Systemic Mastocytosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Masitinib | AB Science | Phase 3 |
| Elenestinib (BLU-263) | Blueprint Medicines | Phase 3 |